SCHEMBL4208508

SCHEMBL4208508

COc1cc(C)ccc1S(=O)(=O)Nc1ccc(OC)c2c1OC[C@H](N(C)C)C2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.49
QRFPR Q96P65 1/20 0.49
MAPK1 P28482 2/20 0.44
ALPL P05186 2/20 0.41
TSHR P16473 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KEAP1 Q14145 1/20 0.40
ALDH1A1 P00352 4/20 0.40
BRD4 O60885 1/20 0.40
USP2 O75604 1/20 0.40
TP53 P04637 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MRGPRX1 Q96LB2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4209903 0.93 HTR6 (0.46) HTR6QRFPRMAPK1TSHRNPSR1
SCHEMBL4207244 0.87 HTR6 (0.43) HTR6QRFPRKEAP1ALDH1A1TP53
SCHEMBL4202359 0.86 HTR6 (0.45) HTR6QRFPRALPLBRD4SMN1; SMN2
SCHEMBL4206086 0.86 BRD4 (0.49) HTR6QRFPRBRD4
SCHEMBL4196203 0.86 HTR6 (0.45) HTR6QRFPRMAPK1TSHRALDH1A1
SCHEMBL4201660 0.85 ALDH1A1 (0.46) HTR6QRFPRNPSR1KEAP1ALDH1A1
SCHEMBL4207471 0.85 ALDH1A1 (0.50) HTR6QRFPRMAPK1ALPLNPSR1
SCHEMBL4216791 0.85 HTR6 (0.46) HTR6QRFPRTSHRALDH1A1BRD4
SCHEMBL4202072 0.85 HTR6 (0.52) HTR6QRFPRMAPK1TSHRNPSR1
SCHEMBL4202352 0.85 HTR6 (0.59) HTR6QRFPRMAPK1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D HTR6 1/4885QRFPR 81/4885MAPK1 3098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.